Introduction
Adenosine diphosphate (ADP) is contained in the dense granules of platelets and is released upon platelet activation by agonists such as collagen, thrombin, and thromboxane A 2 . Released ADP plays a significant role in the potentiation of many platelet responses, including GPIIb/IIIa activation 1 , dense granule secretion 2 , and platelet procoagulant activity [3] [4] [5] , though ADP itself also causes platelet aggregation 6 and thromboxane A 2 generation 7 . While the potentiating effects of ADP have been realized, the signaling mediators for ADP-induced platelet activation are still being identified.
ADP stimulates platelet aggregation by signaling through the P2Y 1 and P2Y 12 receptors 1, [8] [9] [10] . Stimulation of the G q -coupled P2Y 1 receptor leads to PLC activation and subsequent intracellular calcium mobilization 11 . Increased intracellular calcium mobilization causes platelet shape change through a process of filopodial extension and actin reorganization 12, 13 . The P2Y 12 receptor couples to G i and leads to the inhibition of adenylyl cyclase [14] [15] [16] [17] , but also activates PI-3 kinase 18 , RapIb 19, 20 , Akt [21] [22] [23] [24] , and G protein-coupled inwardly rectifying potassium channels (GIRKS) 25 . It is the signaling downstream of this receptor that is predominantly responsible for the potentiation of many platelet responses [26] [27] [28] [29] [30] [31] .
Platelets contain members of the G q , G i , G s , and G 12/13 families of heterotrimeric G proteins 10, 32 . Heterotrimeric G proteins contain , , and subunits, and are classified based on the subunit 33 .We have previously shown that co-stimulation of G q and G i signaling pathways, downstream of the P2Y 1 and P2Y 12 receptors, respectively, leads to platelet aggregation 34 . Recently, we and others have shown that combined signaling of G 12/13 and G i pathways is also sufficient to cause platelet aggregation 35 36 .
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From Mice deficient in G q , G 12 , or G 13 proteins confirm that signaling through multiple G protein pathways are necessary for normal platelet aggregation 37, 38 . G q -deficient mice have platelets that undergo shape change but no aggregation in response to thromboxane A 2 or thrombin, while ADP causes neither shape change nor aggregation 37 . Consistent with observations that G 12/13 signaling is pro-aggregatory when combined with G i signaling, mice deficient in alpha subunit of G 13 have impaired platelet aggregation and granule secretion responses 38 . Mice deficient in the alpha subunit of G 2 have both decreased ADP-induced platelet aggregation and decreased inhibition of adenylyl cyclase, suggesting that the P2Y 12 receptor primarily couples to G i2 17 14 . Mice that are deficient in the alpha subunit of G z have an impaired response to epinephrine-mediated effects, suggesting that the 2A adrenergic receptor couples primarily to G z 39 . Both G i2
and G z belong to the G i class of G proteins 33 . Because the interactions between the multiple G protein pathways has been shown to elicit different effects than either pathway alone, we characterized the functional effects of the G i and G z pathways on platelet activation. We then compared the signaling requirements for G i and G z signaling with those of G q and G i signaling, two pathways simultaneously activated by ADP.
The platelet contains many serine/threonine and tyrosine kinases that are 
Materials and Methods

Materials:
ADP and epinephrine were purchased from Chrono-Log Corp. (Havertown, PA).
Fluorescein isothiocyanate-conjugated monoclonal antibody PAC-1 was purchased from BD Pharmingen. Fura-2, AM was purchased from Molecular Probes (Eugene, OR). The acetoxymethyl ester of 5,5-dimethyl-bis-(o-aminophenoxy)ethane-N',N',N',N' tetraacetic acid (dimethyl BAPTA-AM), LY294002, PP1, PP2, PP3 and Ro 31-8220 were purchased from Biomol (Plymouth Meeting, PA). AR-C 69931MX was a gift from Astra- Animals-G q -deficient mice were acquired from T. Kent Gartner, University of Memphis, with permission from Stefan Offermanns, University of Heidelberg, Germany 37 . P2Y1-deficient mice were generated via subcontract with Lexicon Genetics
Inc. (Woodlands,TX) and were described in our previous publications 23 .
Platelet preparation:
Whole blood was drawn from healthy, consenting human volunteers into tubes containing 1/6 volume of ACD (2.5 g of sodium citrate, 1.5 g of citric acid, and 2 g of glucose in 100 mL of deionized water). Blood was centrifuged (Eppendorf 5810R centrifuge, Hamburg, Germany) at 230 rcf for 20 minutes at room temperature to obtain platelet rich plasma (PRP). PRP was incubated with 1 mM acetylsalicylic acid for 30 minutes at 37°C. The PRP was then centrifuged for 10 minutes at 980 rcf (room temperature) to pellet the platelets. Platelets were resuspended in Tyrode's buffer (138 mM NaCl, 2.7 mM KCl, 1 
Aggregometry and ATP release:
Aggregation of 0.5 mL of washed platelets was analyzed using a P.I.C.A. lumiaggregometer (Chrono-log Corp., Havertown, PA). Aggregation was measured using light transmission under stirring conditions (900 rpm) at 37°C. Agonists were added simultaneously for platelet stimulation, however platelets were pre-incubated with each inhibitor (where noted) as follows: 10 µM Ro 31-8220 for 3 minutes at 37°C and 25 µM LY294002, 10 µM PP1, 10 µM PP2, 10 µM PP3, and 1 µM dimethyl BAPTA-AM for 10 minutes at 37°C. Each sample was allowed to aggregate for at least 3 minutes. 
Intracellular calcium mobilization:
Calcium mobilization was measured in platelets that were loaded with 2 µM fura-2, AM in PRP for 45 minutes at 37°C, and washed platelets were isolated as noted above and brought to a final concentration of 2 X 10 8 platelets/mL in Tyrode's buffer. Samples of Fura-2 AM-loaded platelets (0.5 mL) were placed in a quartz cuvette with a magnetic stirbar, and incubated for 1 minute at 37°C in a temperature-controlled chamber. An Aminco Bowman Series 2 Luminescence Spectrometer was used for measurement of intracellular calcium mobilization. Two wavelengths (340 and 380 nm) were used for Calculation of the calcium mobilization was performed as outlined previously 45 .
Sample Preparation and Western Blotting
Platelets were resuspended in Tyrode's buffer at a concentration of 2 x 10 8 platelets/mL as noted above in "Platelet Preparation." Platelets were stimulated in the presence of 10µM SC57101A, a GPIIb/IIIa antagonist, to eliminate outside-in signaling. Platelets were stimulated with 10µM ADP + 10µM MRS2179 for selective G i signaling, 10µM
epinephrine for G z signaling, or a combination of both for G i and G z signaling. The reaction was stopped with 3X Sample Buffer, boiled for 10 minutes, and platelet lysates were subjected to sodium dodecyl sulfate -polyacrilamide gel electrophoresis (SDS-PAGE) and Western blotting according to a procedure that has been described previously 23 . Membranes were probed with a primary antibody that recognizes Src Tyr416 (1:1000 titer) (Cell Signaling, Beverly, MA, USA) as an indication of Src activity, then probed with an anti-mouse secondary Ab (Kirkegaard and Perry Laboratories, Gaithersburg, Maryland) that is conjugated to alkaline phosphatase. Chemi-luminescence was measured using a Fujifilm LAS-3000 Luminescent Image Analyzer.
Analysis of PAC-1 binding:
Activation of GPIIb/IIIa was measured by PAC-1 mAb binding to washed platelets and subsequent analysis by flow cytometry. Aspirin-treated platelets were isolated by 
Mouse platelet preparation:
C57BL mice were sedated and anesthetized using 0.05 cc ketamine injected intramuscularly into the hind quarter. After induction, blood was drawn from the right ventricle into a 1cc syringe containing 0.1 cc of 3.8% sodium citrate. After drawing the blood, the needle of the syringe was removed (to eliminate shearing of the cells) and the blood was ejected into an Eppendorf tube containing 200 µL of 3.8% sodium citrate.
Blood was centrifuged at 100 rcf for 10 minutes to obtain platelet rich plasma. 3.8% sodium citrate (200 µL) was added to the remaining cells to extract more PRP, and spun at 100 rcf for 10 minutes. PGE 1 (1 µM) was added to the PRP, and was centrifuged at 500rcf for 10 minutes at room temperature to pellet platelets. Platelets were resuspended in 1 mL of Tyrodes containing 0.01 U/mL apyrase.
Measurement of Thromboxane A 2 generation:
Washed, aspirin-treated human platelets were prepared as noted above, and brought to a 
Results
Co-stimulation of G i and G z signaling causes platelet aggregation:
Our laboratory is interested in the G protein signaling pathways that lead to the activation of GPIIb/IIIa and platelet aggregation 34, 35 . We began by measuring the aggregation of washed human platelets to determine if a combination of G i signaling through the P2Y 12 receptor and G z signaling through the 2A adrenergic receptor could cause platelet aggregation. We used a washed aspirin-treated platelet preparation devoid of any plasma proteins to eliminate the positive feedback from generated thromboxane A 2 and thrombin.
The agonist 2-MeSADP, which stimulates both the P2Y 1 completely blocked platelet aggregation that was caused by G i and G z , and also dramatically blocked the aggregation that was caused by G q and G i signaling (Figure 3 ).
The Src family tyrosine kinase inhibitor, PP2, dose-dependently decreased platelet aggregation caused by combined G i and G z stimulation ( Figure 4A ). Platelet aggregation was drastically decreased at the maximal concentration of 10 µM PP2. To confirm the inhibitory effect of Src family tyrosine kinase inhibitors on platelet aggregation, we also tested PP1, a Src-family tyrosine kinase inhibitor, and PP3, a control compound that does not inhibit tyrosine kinase activity. Whereas PP1 decreased the extent of aggregation caused by combined G i and G z signaling, the control compound PP3 had no effect ( Figure 4B ). On the other hand, PP1, PP2, or PP3 did not have a 
Effect of co-stimulation of G i and G z signaling pathways on thromboxane generation:
There was a marked difference in the extent of platelet aggregation of non-aspirin-treated platelets versus aspirin-treated platelets when treated with combined G i and G z signaling ( Figure 6 ). ADP alone caused platelet aggregation in both aspirin-treated and nonaspirin-treated platelets, though selective G i or G z stimulation alone failed to cause platelet aggregation. The aggregation stimulated via G i and G z signaling was significantly more robust in non-aspirin-treated human platelets compared to aspirin- (Figure 6 ). Whereas ADP caused dense granule release in non-aspirintreated human platelets, either G i or G z stimulation alone did not lead to dense granule release. Thromboxane from combined G i and G z stimulation resulted in dense granule release in the non-aspirin-treated platelets, but not in the aspirin-treated human platelets (data not shown).
Because the difference in platelet aggregation was dependent on aspirin, we continued by measuring thromboxane generation after combined G i and G z signaling. A competitive ELISA assay was used to quantitate the amount of thromboxane A 2 generation that occurred after 3.5 minutes of stimulation. Because of the short half-life of generated thromboxane A 2 , samples were probed for their thromboxane B 2 content, a more stable product that reflects thromboxane A 2 production. Either G i or G z stimulation alone generated similar levels of thromboxane compared with unstimulated human platelets ( Figure 7A ). Combined G i and G z stimulation caused a sizeable increase in thromboxane A 2 generation compared with the thromboxane levels generated by 100 nM 2-MeSADP ( Figure 7A ). Src-family tyrosine kinase inhibition decreased the aggregation caused by combined G i and G z stimulation (Figure 4) . We, therefore, tested the effect of PP2 on thromboxane generation from combined stimulation of these pathways. Src family tyrosine kinase inhibition completely inhibited thromboxane production in human platelets from combined G i and G z signaling ( Figure 7B ). To confirm that there was no contribution from P2Y 1 receptor signaling, we performed the same experiment in P2Y 1 -/-mice. Similar to human platelets, thromboxane was generated in P2Y 1 -deficient mouse platelets only when G i and G z signaling were combined ( Figure 7C ). This confirms that For personal use only. on September 24, 2017. by guest www.bloodjournal.org From co-stimulation of the P2Y 12 and 2A adrenergic receptors is also sufficient to cause thromboxane generation in mouse platelets. Similar to human platelets, pre-treating the mouse platelets with 10 µM PP2 inhibited the thromboxane production that resulted from combined G i and G z stimulation ( Figure 7C ).
It has previously been reported that fibrinogen must be present for ADP to cause thromboxane generation in platelets 46 . We noted that fibrinogen was also necessary for thromboxane production via combined G i and G z signaling( Figure 7D ). In the absence of fibrinogen, thromboxane levels were comparable to unstimulated samples. We also used a GPIIb/IIIa antagonist, SC57101, in the presence of fibrinogen, to test if the effect of fibrinogen was GPIIb/IIIa-specific. The GPIIb/IIIa antagonist blocked thromboxane production when fibrinogen was present, suggesting that fibrinogen interations with GPIIb/IIIa are necessary for thromboxane generation via combined G i and G z signaling ( Figure 7D ).
Discussion
The G i signaling pathway is central to platelet activation, primarily because the Gi and G z pathways couple to many of the same effectors, there still remains the possibility that these pathways signal through distinct signaling pathways. However, there is no published evidence for this.
Our work, and work by others, has shown that partial irreversible platelet aggregation occurs with the co-activation of the G 12/13 and G i pathways 35, 36 . Though 100 µM ADP has been reported to cause platelet aggregation in the absence of any calcium mobilization in mouse platelets 47 , we have found that a combination of low-level P2Y 12 receptor and 2A adrenergic receptor stimulation results in a small increase in calcium in human platelets, which is similar to our previous work with combined G 12/13 and G i stimulation 35 . The mechanism of this increase of intracellular calcium is presently unclear, however -mediated activation of PLC or calcium leakage resulting from inhibition of adenylyl cyclase are two possibilities. Chelation of intracellular calcium moderately decreased the extent of aggregation for G i plus G z signaling, while ADPmediated signaling through G q and G i was completely inhibited by intracellular calcium chelation.
Calcium is known to play a significant role in thromboxane A 2 generation in platelets 48 . The thromboxane A 2 generated by 2-MeSADP was consistently less than the levels generated with combined G i and G z stimulation in human platelets. This is unexpected primarily because ADP mobilizes higher levels of intracellular calcium through the G q -coupled P2Y 1 receptor, than the combined signaling through G i and G z 41 . This suggests that multiple agonists stimulate GPIIb/IIIa activity that is partially regulated by tyrosine kinase activity. The Src family tyrosine kinase inhibitor PP1 also inhibited the aggregation caused by combined G i and G z signaling, while the control compound PP3 had no effect on this aggregation ( Figure 4B ). PAC-1 binding, which is indicative of GPIIb/IIIa activation 49 , resulted from combined stimulation of G i and G z signaling. Src tyrosine kinase inhibition led to a decrease in PAC-1 binding, suggesting that tyrosine kinases have a role in the modulation of GPIIb/IIIa activity downstream of these two pathways. Notably, PP2 did not completely inhibit the platelet aggregation or GPIIb/IIIa activation that is caused by co-stimulation of G i and G z signaling. Therefore, while Src-family tyrosine kinases may increase the extent of GPIIb/IIIa activation, they are not absolutely necessary for GPIIb/IIIa activation.
Recent work has measured Src activity that occurs downstream of ADP-mediated stimulation 50 . This work showed that ADP-mediated Src activation is activated primarily by the P2Y 1 receptor, but did not consider that ADP-mediated Src activation is still increased above baseline when ADP is signaling solely through the P2Y 12 receptor 50 .
Thus, it appears that both the P2Y 1 and P2Y 12 receptors are able to cause Src activation through G q and G i signaling respectively, albeit to different levels. Our data illustrates that Src is activated downsteam of the P2Y 12 receptor and the 2A adrenergic receptor.
Thus, either G i or G z signaling is sufficient to activate Src, and this Src activity plays a role in the level of GPIIb/IIIa activation.
Multiple enzymes have been implicated in the regulation of PLA 2 including protein kinase C, 51 , MAP kinases 52 , and calcium 53 , though the candidates that phosphorylate and activate PLA 2 remain the subject of controversy. Lyn-deficient mice have impaired thromboxane generation in response to -thrombin when compared to wild type mice 42 . Thus, Src family tyrosine kinases play a role in the generation of thromboxane A 2 in platelets that are activated by G i and G z signaling pathways, though it is presently unclear how proximal this family of kinases is to PLA 2 activation.
ADP requires signaling through the P2Y 1 receptor, P2Y 12 receptor, and outside-in signaling through GPIIb/IIIa to cause thromboxane A 2 generation 46 . Similarly, we have found that combined P2Y 12 receptor and 2A adrenergic receptor stimulation causes thromboxane A 2 generation with a requirement for outside-in signaling through GPIIb/IIIa. An alternative explanation is that post-aggregatory events may be necessary for thromboxane generation, and that fibrinogen is facilitating platelet-to-platelet contact for the post-aggregatory response. We cannot presently differentiate between the two because of limited knowledge regarding post-aggregatory events.
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While G 12/13 , G q , or G z can interact with P2Y 12 -mediated G i signaling to cause platelet aggregation, the signaling intermediates for these pathways differ (illustrated in Figure 7E ). PI-3 kinases and Src family kinases are pro-aggregatory signals for G i plus al. 50 , we speculate that Src family kinases are upstream of the PI-3 kinases. The diversity in the signaling of these somewhat non-redundant pathways may serve as a protection from deficiencies, but also allow multiple pro-aggregatory signals to contribute to this highly complex, fine-tuned system. 
